eye was normal. The left eye anterior segment showed corneal endothelial dusting, 3+ anterior chamber cells, moderate flare, and pigment on anterior lens surface. Fundus evaluation of the left eye showed dense vitritis with vitreous membranes and a submacular abscess [ Fig. 1a ]. There was no history of ocular trauma or surgery. There was history of hospitalization and intravenous infusion of normal saline for fever and dehydration 1 month ago. There were no features suggestive of any systemic illness. With a probable diagnosis of contaminated intravenous infusion-related EE of the left eye, the patient was admitted for systemic workup. Systemic examination by an internist did not reveal any focus of infection, and the patient was afebrile. Complete blood counts and liver and renal function tests were within normal limits, and blood and urine cultures were sterile. A diagnostic pars plana vitrectomy (PPV) was performed in the left eye with intravitreal amphotericin B (5 µg/0.1 ml) + dexamethasone (400 µg/0.1 ml). The vitreous fluid samples were sent for bacterial and fungal smears and cultures. The potassium hydroxide (KOH) mount of vitreous sample revealed septate hyphae with branching at acute angles, and the panfungal polymerase chain reaction was positive [ Fig. 1b and c]. Oral itraconazole 200 mg BD was started. Following an initial improvement, and after five injections of intravitreal amphotericin B with dexamethasone, his vision deteriorated with worsening of vitritis and an increase in the size of submacular abscess at 4 weeks [ Fig. 2a ]. The culture showed growth of a fungus which was not sporulating. Molecular sequencing of this growth was done with partial internal transcribed spacer-1 gene as the target gene. Direct sequencing of the amplicon was done using bidirectional Sanger's method. The sequence was checked with public database of NCBI, which found a 100% match with Lecythophora species. Oral voriconazole 200 mg BD was started in place of itraconazole. Five weekly injections of intravitreal voriconazole (100 µg) were given. Oral voriconazole was stopped after 3 months. At 6-month follow-up, the visual acuity was counting fingers at 2 meters, with a quiet eye and macular scar [ Fig. 2b ].
Discussion
Ocular involvement by Lecythophora has been reported in the form of bleb-related endophthalmitis, [5] after corneal cyanoacrylate glue application and after deep anterior lamellar keratoplasty. [6, 7] Lecythophora is a mold that lacks a known sexual state and is thus categorized under Fungi Imperfecti. It is generally classified as a dematiaceous fungus which is mainly attributed to its darkly colored fungal body due to the presence of melanin in the cell walls of its conidia, hyphae, or both and is ubiquitous in nature. [9] Lecythophora species (L. mutabilis, Lecythophora hoffmannii, and Lecythophora lignicola) are cosmopolitan and are occasionally isolated from soil and from plant debris. L. mutabilis has been described to be the causative agent of human peritonitis, endocarditis, endophthalmitis, and keratitis. It is sensitive to voriconazole (systemic and intravitreal) and resistant to amphotericin B. [10] 
Conclusion
Besides the clinical and diagnostic challenges of other EE (fungal or bacterial), this case posed significant diagnostic and therapeutic challenges despite an early KOH report suggesting a fungal cause of EE. First, this is a rare fungus and was never considered in the differential diagnosis in our case as it has never been reported to cause EE. Second, it is difficult to detect because of poor growth on culture. Third, its resistance to conventional empirical antifungal therapy with amphotericin B poses treatment issues. Therefore, a high index of suspicion, as in any case of EE, should be kept while dealing with cases with severe infection in the eye, a recent history of hospitalization or intravenous infusion, an immunocompetent patient, and a persistent infection in the eye despite an early antifungal treatment. In the absence of culture showing any definitive results, a more aggressive approach by the microbiologist in the form of molecular sequencing can salvage the eye by revealing a rare pathogen causing EE.
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Toxoplasma retinitis following intravitreal injection of triamcinolone acetonide: A case report and review of literature

Arshee Ahmed, Sridharan Sudharshan, Sriram Gopal 1 , Parthopratim Dutta Majumder, Jyotirmay Biswas
The aim of this study was to report a case of atypical toxoplasma retinochoroiditis following intravitreal triamcinolone acetonide (IVTA) injection and to review the literature pertaining to toxoplasma retinochoroiditis following intravitreal injection of corticosteroid. Clinical data were collected from a 64-year-old male who developed toxoplasma retinitis 2 months after IVTA. A review of the literature was conducted to identify additional reports on similar cases. A 64-year-old male, known diabetic with nonproliferative diabetic retinopathy in both the eyes and optic atrophy in the left eye, presented with atypical retinitis inferior to the disc following IVTA. Real-time polymerase chain reaction and serology confirmed the toxoplasma etiology, and the patient was started on anti-toxoplasma therapy along with oral corticosteroid leading to regression of the lesion by 3 months. A high index of suspicion and proper microbiological diagnosis with appropriate antimicrobial therapy can aid in the management of toxoplasma retinochoroiditis following intravitreal injection of corticosteroid.
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Intravitreal corticosteroids have been in use for various conditions such as diabetic macular edema, vein occlusions, pseudophakic cystoid macular edema, and a variety of uveitic diseases. Common adverse events include cataract formation and steroid-induced glaucoma, endophthalmitis, vitreous hemorrhage, and retinal detachment. There have been reports of infective uveitis following injection of intravitreal corticosteroids in recent years. [1] [2] [3] [4] Although majority of them reported a viral etiology, [1, [4] [5] [6] [7] rare presentations of acute syphilitic posterior placoid chorioretinitis [2, 8] and toxoplasma retinochoroiditis [3, 9] following intravitreal injection of corticosteroid have been reported.
Typical toxoplasma lesions include unilateral focal retinochoroiditis at the border of a preexisting pigmented retinochoroidal lesion and overlying vitritis. However, atypical lesions may consist of large areas of retinal necrosis or retinochoroiditis without adjacent preexisting pigmented retinal scar or retinochoroiditis in both the eyes. Such atypical lesions are seen in elderly individuals and in those with underlying immunodeficiency due to various causes. [10] We report an unusual case of an atypical toxoplasma retinochoroiditis after intravitreal triamcinolone acetonide (IVTA) injection in an elderly diabetic patient. A detailed review of the literature on PubMed was conducted using such terms as intravitreal, corticosteroid, toxoplasma retinochoroiditis, and ocular toxoplasmosis. Additional studies were also looked for from the bibliographies of the retrieved articles.
Case Report
A 64-year-old male presented to our uveitis clinic with complaints of blurring of vision in the right eye of 10-day duration. He was a known diabetic for 14 years and documented to have nonproliferative diabetic retinopathy in both the eyes and optic atrophy (due to probable ischemic optic neuropathy) in the left eye for 4-year duration. IVTA
